Web Results

law.justia.com/cases/federal/district-courts/delaware/dedce/1:2014cv01317/55946/389

Jan 3, 2017 ... Amgen Inc. et al v. Sanofi et al, No. 1:2014cv01317 - Document 389 (D. Del. 2017) case opinion from the District of Delaware US Federal District Court.

law.justia.com/cases/federal/appellate-courts/ca3/16-3668/16-3668-2017-12-06.html

Dec 6, 2017 ... Sanofi Aventis US LLC v. Great American Lines Inc, No. 16-3668 (3d Cir. 2017) case opinion from the US Court of Appeals for the Third Circuit.

www.courtlistener.com/opinion/2659199/russo-v-sanofi-aventis-us-ca25

Apr 1, 2014 ... IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA SECOND APPELLATE DISTRICT DIVISION FIVE JAMI RUSSO, B246717 Plaintiff and Appellant, (Los Angeles County Super. Ct. No. BC435846) v. SANOFI-AVENTIS, U.S. etc. et al., Defendants and Respondents. APPEAL from a judgment of ...

ecf.ksd.uscourts.gov/cgi-bin/show_public_doc?2017md2785-98

April 24, 2017. Sanofi-Aventis U.S. LLC v. Mylan Inc., et al., Case No. 3:17-cv- 02763-FLW-. TJB (D.N.J. Apr. 24, 2017), ECF 1 (“Sanofi Complaint”). The Sanofi Complaint alleges that. Mylan engaged in a variety of anticompetitive conduct designed to prevent Auvi-Q. ®. —a rival product once sold by Sanofi—from gaining ...

search.rpxcorp.com/litigation_documents/12379480

Sanofi-Aventis U.S. LLC and Genzyme Corporation (collectively, “Sanofi”), and. Regeneron Pharmaceuticals, Inc. ... This is an action seeking a declaration that Sanofi and Regeneron's development, manufacturing, sale .... See Corren, et al., “A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-. 4α Antagonist, in  ...

www.cafc.uscourts.gov/sites/default/files/opinions-orders/17-1480.Opinion.10-2-2017.1.PDF

Oct 5, 2017 ... Appellants Sanofi, Aventisub LLC, Regeneron Phar- maceuticals Inc., and Sanofi -Aventis U.S., LLC (collective- ly, “Appellants”) appeal from a final judgment of the district court holding U.S. Patent Nos. 8,829,165 (“'165 patent”) and 8,859,741 (“' 741 patent”) not invalid and granting a permanent injunction ...

caselaw.findlaw.com/us-3rd-circuit/1733563.html

May 4, 2016 ... Eisai complains that the conduct of Sanofi Aventis U.S., LLC, and Sanofi U.S. Services, Inc., (Sanofi) jointly and severally harmed competition in the market ... The formulary access clause in the Lovenox contract required customers to provide Lovenox with unrestricted formulary access for all FDA-approved ...

antitrustconnect.com/2016/05/16/eisai-v-sanofi-aventis-third-circuit-leaves-door-open-to-loyalty-discount-liability

May 16, 2016 ... In one sense the decision of the Third Circuit in Eisai v Sanofi-Aventis on 4 May was fairly unremarkable. Like those before it in Concord Boat, Allied Orthopedic, Southeast Missouri Hospital and others, the court rejected Eisai's allegation that Sanofi's loyalty discounts were an anticompetitive de facto ...

jc6kx1c9izw3wansr3nmip8k-wpengine.netdna-ssl.com/wp-content/uploads/2018-01-26-Report.pdf

Jan 26, 2018 ... Sanofi-Aventis U.S. LLC et al. 2:17-cv-00539. Carson v. Sanofi S.A. et al. 2:16-cv- 15322. Carter v. Sanofi S.A. et al. 2:17-cv-00047. Carver v. Sanofi S.A. et al. 2:16- cv-17192. Caye v. Sanofi S.A. et al. 2:17-cv-04726. Champagne v. Sanofi S.A. et al. 2:16-cv-17174. Chappell v. Sanofi S.A. et al. 2:16-cv-17163.